Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024


Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1?5, 2024.

Natera and its collaborators will present 18 abstracts highlighting new Prospera data across heart, lung, kidney, and multi-organ transplantation. This includes an oral presentation highlighting the predictive capabilities of the Prospera Kidney test from the ProActive study, the largest prospective dd-cfDNA study in kidney transplant recipients.

"We look forward to sharing new research at ATC that demonstrates the breadth of clinical evidence supporting Prospera across multiple organ types," said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera. "This includes new data from the landmark ProActive study, reinforcing the value of the Prospera Kidney test as a highly accurate surveillance tool for detecting ongoing organ rejection and predicting future rejection."

Highlights from selected abstracts include:

Additionally, Natera will host a lunch symposium on June 2nd from 12:15 - 1:15 PM ET titled, "Monitoring matters: Latest data supporting Prosperatm dd-cfdna for routine kidney transplant care." It will include participation from Zahraa Hajjiri, MD, assistant professor of medicine, interim UNOS medical director, Transplant Nephrology, AST Transplant Nephrology Fellowship Director, University of Illinois-Chicago, Anil Chandraker, MD, professor of medicine, UMass Chan School of Medicine, chief, division of Renal Medicine, UMass Memorial Health Care, and Ali Zarrinpar, MD, PhD, professor, University of Florida College of Medicine, University of Florida Health.

The data being presented at ATC adds to the growing body of research supporting Natera's organ health tests, which includes over 40 peer-reviewed publications.

About the Prospera test

The ProsperaTM test leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation.

About Natera

NateraTM is a global leader in cell-free DNA testing and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, or our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.


These press releases may also interest you

at 01:07
ROLLER, a leading provider of venue management software for the attractions industry, is excited to announce its new integration with Workforce.com (also known as Tanda in Australia), a global industry-leading payroll, scheduling, HR and workforce...

at 01:05
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap. The license updates, issued following...

at 01:00
DNA Health & Wellness, the MENA region's first and largest health optimisation and longevity clinic group, is set to open its new clinic in Abu Dhabi in the third quarter of 2024. The new state-of-the-art facility will span over 10,000 sq. ft and...

at 00:15
In a continuing series of laureate announcements, the Tang Prize Foundation today (June 19th) announced the 2024 Tang Prize in Biopharmaceutical Science recipients. The prestigious award has been jointly awarded to Joel F. Habener, Svetlana Mojsov,...

at 00:05
Resecurity (USA), a global leader in cybersecurity solutions serving major Fortune 500 companies and government agencies, is excited to announce the rollout of its innovative Digital Identity Protection (IDP) solution in Singapore. Being one of the...

18 jun 2024
XTM Inc. ("XTM" or the "Corporation") (QB: XTMIF / CSE: PAID / FSE: 7XT) is providing an update to its previously announced management cease trade order (the "MCTO") granted by the Ontario Securities Commission (the "OSC") under National Policy...



News published on and distributed by: